UPDATE: CMS passes NTAP reimbursement for LivaNova ’ s Perceval, Edwards Intuity aortic valves

Updated to include that the CMS NTAP also covered Edwards Lifescience’s Intuity suturless aortic valve The Centers for Medicare and Medicaid Services today released its Final Rule for FY2018 Medicare Inpatient Payment and Policy, granting New Technology Add-On Payment reimbursement for rapid deployment valves, including LivaNova‘s (NSDQ:LIVN) Perceval and Edwards Lifesciences‘s (NYSE:EW) Intuity aortic valves. London-based LivaNova said that the Perceval sutureless valve had met the CMS criteria for the add-on payment, including showing substantial clinical improvement over existing technologies. With the reimbursement approval, CMS will begin to reimburse hospitals for the Perceval valve procedure with the normal Medicare Severeity Diagnosis Related Group payment as well as an additional $6,110.23, LivaNova said. “We are pleased CMS recognized the significant value of the Perceval valve in the management of aortic valve disease. Numerous publications in the medical literature have demonstrated the benefits of the Perceval valve compared to traditional surgical valves, and this decision will provide greater access to this important new technology. We look forward to continuing to provide the latest and most clinically beneficial technologies to cardiac surgeons and their patients,” cardiac surgery biz medical affairs VP Dr. Brian Duncan said in a press release. LivaNova said that clinical data from trials of the valve showed that its use resul...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Cardiac Implants Cardiovascular Replacement Heart Valves Centers for Medicare and Medicaid Services (CMS) Edwards Lifesciences LivaNova Source Type: news